IPO Year: 2024
Exchange: AMEX
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. In his role, Dr. Shor will assist the Company in the selection of antibody and payloads to be developed using the Company's tunable ADC platform leveraging its proprietary pH-sensitive SiLinker™ silicone linker technology. Dr. Shor has 20 years of experience in leading oncology discovery programs and external R&D partnerships at large pharma (Pfizer, Wyeth) and biotech companies, with specific focus on preclinical discovery and development of sma
3 - OS Therapies Inc (0001795091) (Issuer)
3 - OS Therapies Inc (0001795091) (Issuer)
4 - OS Therapies Inc (0001795091) (Issuer)
4 - OS Therapies Inc (0001795091) (Issuer)
8-K - OS Therapies Inc (0001795091) (Filer)
10-Q - OS Therapies Inc (0001795091) (Filer)
NT 10-Q - OS Therapies Inc (0001795091) (Filer)
S-1 - OS Therapies Inc (0001795091) (Filer)
8-K - OS Therapies Inc (0001795091) (Filer)
8-K - OS Therapies Inc (0001795091) (Filer)
8-K - OS Therapies Inc (0001795091) (Filer)
8-K - OS Therapies Inc (0001795091) (Filer)
10-Q - OS Therapies Inc (0001795091) (Filer)
SC 13G - OS Therapies Inc (0001795091) (Subject)
Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of 2024 ended September 30, 2024 and provided a business update. "The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in our Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma," said Paul Romness, MHP, Chairman & CEO of OS Therapies. "We are now looking forward
OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at The Spartan Capital Investor Conference. The conference is being held on November 4, 2024 at the Pierre Hotel in New York. The Company's participation aligns with our commitment to engage with industry leaders and investors. Event: The Spartan Capital Investor Conference Presentation Date: Monday, November 4, 2024 Time: 4:45 PM ET Mr. Romness
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, is pleased to invite investors to a webinar on October 30, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature OS Therapies' Chairman and CEO Paul Romness, and Chief Business Officer Gerald Commissiong. They will share insight into the Company's pipeline of novel treatments for Osteosarcoma (OS) and other solid tumors. Through innovative product candidates, OST-HER2 and OST-tADC, OS Therapies is not only addressing a significant gap in pediatric and young adult cancer care but also expanding its therapeutic
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVII Presentation Date: Tuesday, October 29, 2024 Time: 11:30 AM PT Register to watch presentation: https://me24.sequireevents.com/ Mr. Romness and Mr. Commissiong will be avail
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, will be presenting at the 2024 Maxim Healthcare Virtual Summit. The summit is being held virtually on October 15 – 17, 2024. Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17, 2024 Time: 3:00 PM ET Webcast: https://m-vest.com/events/healthcare-10152024 About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (O
Company to ring Closing Bell at NYSE on Thursday, October 3, 2024 Interviews scheduled with Fintech.TV and Schwab Network OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation at 52 weeks and the treatment period for the clinical trial has now ended. The Company is preparing to request a Type C Meeting with the U.S. Food & Drug Administration (FDA) and to make any protocol adjustments based o
First therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric Cancer Second therapeutic candidate targets platinum-resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the Company's proprietary SiLinker™ technology. The Company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will target Breast, Lung and Ga
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancerStrong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancerStrong safety profile for FRA-H with no loss of bodyweight as compared with control in animal modelsSuccess of tADC proof-of-concept study paves way for creating multiple potential therapeutic candidates for preclinical and clinical evaluation NEW YORK, NY / ACCESSWIRE / September 11, 2024 / OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced positive data in animal models of ovarian
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. The Company's President & CEO Paul Romness, MPH, will deliver a virtual presentation highlighting the Company's potentially pivotal fully-enrolled Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 in the prevention of resected, recurrent human osteosarcoma, OST-HER2's pending pivotal safety study in the treatment of canine osteosarcoma and the Company's tunable Antibody Dr